Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy · 2021
COVID-19-associated pulmonary aspergillosis in a Japanese man: A case report.
Клинический случайСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Imoto Waki, Himura Hoshi, Matsuo Kenji, Kawata Sae, Kiritoshi Ayako, Deguchi Ryo, Miyashita Masahiro, Kaga Shinichiro, Noda Tomohiro, Yamamoto Katsumi, Yamada Koichi, Uchida Kenichiro, Nishimura Tetsuro, Yamamoto Hiromasa, Mizobata Yasumitsu, Kakeya Hiroshi
Аннотация
CAPA (COVID-19 associated pulmonary aspergillosis) is an important complication of COVID-19. It has been reported that the incidence of CAPA is as high as 19%-33% worldwide. However, its onset has not been reported in Japan. A 72-year-old Japanese man was diagnosed with COVID-19 and was transferred to our hospital due to deterioration of respiratory condition. Treatment with remdesivir, dexamethasone (DEXA), and antibiotics was performed under mechanical ventilation. Although the condition improved temporarily, a new shadow appeared in the lung, and Aspergillus fumigatus was cultured from sputum. The patient was clinically diagnosed with CAPA and treated with voriconazole. However, his progress deteriorated and he died. High-risk COVID-19 patients should be tested for Aspergillus to ensure early diagnosis of CAPA.